GHRS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders...

Stats
Today's Volume	32 008.00
Average Volume	127 303
Market Cap	546.30M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.220 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.44
ATR14	$0.0300 (0.29%)

Volume Correlation

Long: 0.14 (neutral)

Short: -0.09 (neutral)

Signal:(45.671) Neutral

GH Research PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GH Research PLC Correlation - Currency/Commodity

0.12
( neutral )

-0.10
( neutral )

0.00
( neutral )

0.35
( neutral )

-0.42
( neutral )

0.22
( neutral )

GH Research PLC Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-315 000 (0.00 %)
EPS:	$-0.680

FY	2023
Revenue:	$0
Gross Profit:	$-315 000 (0.00 %)
EPS:	$-0.680

FY	2022
Revenue:	$0
Gross Profit:	$-47 000.00 (0.00 %)
EPS:	$-0.140

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.211

Financial Reports:

No articles found.

GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.